To reach the next value inflection
LicenseRx asset brief
Histone Deacetylase and DNA Methyltransferase Inhibitors for Preventative Cardiac Care and Ischemic Injury Treatment
Probability of Success
23% · grade C · Medium data confidence
Model PoS 23% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: Translational evidence.
Data maturity (22%)
54
Preclinical; limited public evidence of validation.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
74
Cardiometabolic -- active buyer appetite.
Competitive whitespace (12%)
74
Multi-modal differentiation.
Translational evidence (12%)
46
No translational evidence keywords in the public summary -- lab-stage claim.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →